2023 - Research.com Neuroscience in Ireland Leader Award
2003 - Member of the Royal Irish Academy
His primary scientific interests are in Psychosis, Internal medicine, Psychiatry, Schizophrenia and Dopamine receptor. His Psychosis research integrates issues from Psychosocial, Cerebro, Course of illness, Neuroscience and Craniofacial. In his study, Agonist and Denervation supersensitivity is strongly linked to Endocrinology, which falls under the umbrella field of Internal medicine.
John L. Waddington interconnects Disease, Cohort study and Clinical psychology in the investigation of issues within Psychiatry. His Schizophrenia study combines topics in areas such as Genetics, Dyskinesia, Family history and Genome-wide association study. His Dopamine receptor research incorporates themes from Dopaminergic, Pharmacology and D-1.
The scientist’s investigation covers issues in Schizophrenia, Psychosis, Psychiatry, Neuroscience and Internal medicine. His studies deal with areas such as Bipolar disorder, Dyskinesia, Cognition and Clinical psychology as well as Schizophrenia. His research integrates issues of Antipsychotic, Disease, Etiology and Cognitive disorder in his study of Psychosis.
The study incorporates disciplines such as Phenotype, Neuregulin 1 and Schizophrenia in addition to Neuroscience. Phenotype is a subfield of Genetics that he explores. His research in Internal medicine tackles topics such as Endocrinology which are related to areas like Agonist.
His main research concerns Schizophrenia, Psychosis, Neuroscience, Psychiatry and Internal medicine. His Schizophrenia research is multidisciplinary, incorporating elements of Phenotype, Bipolar disorder, Cognition, Disease and Clinical psychology. His Psychosis research is multidisciplinary, relying on both Movement disorders and DNA methylation.
His study in the field of Working memory, Habituation and Basal ganglia is also linked to topics like Context. His research investigates the connection between Internal medicine and topics such as Endocrinology that intersect with issues in Agonist, DISC1 and Neuregulin 1. The subject of his Genome-wide association study research is within the realm of Genetics.
His primary areas of investigation include Schizophrenia, Psychosis, Neuroscience, Internal medicine and Bipolar disorder. His research in Schizophrenia intersects with topics in Dentate gyrus, Phenotype, Habituation, Dysbindin and Clinical psychology. His Psychosis study which covers Disease that intersects with Neurodevelopmental disorder.
His Neuroscience study incorporates themes from Developmental psychology and Genetic model. His Internal medicine research incorporates elements of Endocrinology, Gene expression and DISC1. His work carried out in the field of Bipolar disorder brings together such families of science as Major depressive disorder, Genetic heterogeneity, Genome-wide association study and Genetic association.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Biological insights from 108 schizophrenia-associated genetic loci
Stephan Ripke;Stephan Ripke;Benjamin M. Neale;Benjamin M. Neale;Aiden Corvin;James T. R. Walters.
Rare chromosomal deletions and duplications increase risk of schizophrenia
Jennifer L. Stone;Jennifer L. Stone;Jennifer L. Stone;Michael C. O’Donovan;Hugh Gurling;George K. Kirov.
Analysis of shared heritability in common disorders of the brain
Verneri Anttila;Verneri Anttila;Brendan Bulik-Sullivan;Brendan Bulik-Sullivan;Hilary K. Finucane;Raymond K. Walters;Raymond K. Walters.
Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores
Bjarni J. Vilhjálmsson;Jian Yang;Hilary K. Finucane;Alexander Gusev.
American Journal of Human Genetics (2015)
Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects
Christian R Marshall;Daniel P Howrigan;Daniel P Howrigan;Daniele Merico;Bhooma Thiruvahindrapuram.
Nature Genetics (2017)
Dopaminergic behaviour stereospecifically promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390
Anthony G. Molloy;John L. Waddington.
Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes
Douglas M. Ruderfer;Stephan Ripke;Stephan Ripke;Stephan Ripke;Andrew McQuillin;James Boocock.
Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects
Eva M Jimenez-Mateos;Tobias Engel;Paula Merino-Serrais;Ross C McKiernan.
Nature Medicine (2012)
Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study.
John L. Waddington;Hanafy A. Youssef;Anthony Kinsella.
British Journal of Psychiatry (1998)
Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse.
Shelley A. Ross;John Y. F. Wong;Jeremiah J. Clifford;Anthony Kinsella.
The Journal of Neuroscience (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: